Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Latigo reports Q2 2026 results, NEJM publication for onzotrigine, and completed IPOSep 3Quarterly updateLatigo Biotherapeutics